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Abstract 
Adult-onset Leigh syndrome is a rare but important manifestation of mitochondrial disease. 
We report a 17 year old female who presented with subacute encephalopathy, brainstem and 
extrapyramidal signs, raised CSF lactate, and symmetrical hyperintensities in the basal 
ganglia on T2-weighted cerebral MRI. The presence of cytochrome c oxidase deficient fibres 
in muscle tissue prompted sequencing of the entire mitochondrial genome which revealed the 
novel stop codon mutation m.6579G>A; p.Gly226X in MT-CO1. Here we present the case 
and review the clinicopathological and molecular spectrum of previously reported MT-CO1 
truncating mutations. 
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1. Introduction 
Mitochondrial disorders are a phenotypically diverse group of diseases caused by genetic 
defects that impair oxidative phosphorylation (OXPHOS). Cytochrome c oxidase (COX, 
complex IV), the terminal component of the mitochondrial electron transport chain (ETC), 
catalyses the reduction of molecular oxygen to water and helps establish the proton gradient 
across the inner mitochondrial membrane required for ATP synthesis. The catalytic core of 
COX is composed of three subunits (COX I-III), encoded by the mitochondrial genome (MT-
CO1-3), and their prosthetic groups. COX I, II and III are surrounded by 11 nuclear-encoded 
subunits, many of which are expressed as tissue-specific isoforms, that are suggested to 
perform an insulating or regulatory role1. Assembly of the COX holoenzyme is a complex 
module-based process that occurs around COX I-III2. 
  
Over 50 pathogenic mutations, including 14 truncating mutations, are reported in MT-CO1-3 
and are associated with a broad clinical spectrum of disease that includes sideroblastic 
anaemia, sensorineural deafness, intractable epilepsy, mitochondrial encephalomyopathy, 
lactic acidosis and stroke-like episodes (MELAS), and mitochondrial myopathy (MitoMap3).  
Here we report a patient with adult-onset Leigh syndrome in whom the previously unreported 
stop codon mutation m.6579G>A in MT-CO1 was detected. We also review the phenotypic 
spectrum associated with MT-CO1 truncating mutations and discuss the potential 
mechanisms that contribute towards their clinical heterogeneity. 
 
2. Patient and Methods 
2.1 Clinical case 
A 28 year old female presented aged 17 years with a subacute encephalopathy, preceded by a 
viral gastrointestinal illness, associated with diplopia, dizziness, dysarthria, and hearing loss. 
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Cranial nerve examination revealed abnormal eye movements, bilateral lower motor neuron 
facial weakness, and bulbar dysfunction. There were extrapyramidal and pyramidal signs in 
the limbs with no evidence of cerebellar or sensory disturbance. She recovered fully after the 
acute phase of the illness but subsequently developed a transient unilateral facial weakness 
and persistent fatigue. Past medical history included a possible seizure and episode of 
confusion following a childhood vaccination. A maternal uncle had epilepsy but there was no 
other family history of neurological, neuromuscular or multisystem disease (Figure 1A).  
 
Laboratory tests at initial presentation, including blood lactate, ammonia, CPK, ESR, HIV, 
Lyme serology, copper and caeruloplasmin, ASO titres, amino acids, ANA, ANCA, anti-
cardiolipin and anti-basal ganglia antibodies, and urinary organic and amino acids were 
normal. CSF was acellular, glucose was normal and oligoclonal bands were negative. 
However, CSF protein and lactate levels were raised (0.45g/L, reference range 0.17-0.36g/L 
and 3.06mmol/L, reference range 0.8-1.9mmol/L respectively). 
 
Cerebral MRI initially showed high T2 signal intensities in the basal ganglia bilaterally, 
predominantly affecting the putamen and globus pallidus, without gadolinium enhancement. 
Repeat cerebral MRI brain 10 weeks after the acute phase of the illness confirmed resolution 
of the acute changes (Figure 1B and C). An EEG demonstrated a resolving encephalopathy. 
Nerve conduction studies revealed a mild generalised polyneuropathy with demyelinating 
features, while EMG was normal. 
 
2.2 Skeletal muscle histochemical, biochemical and molecular genetic studies 
Muscle biopsy of the vastus lateralis was performed following informed consent aged 18 
years. Standard muscle section staining was undertaken, including COX and modified 
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Gomori trichrome. Mitochondrial respiratory chain enzyme activities were measured by 
spectrophotometric analysis. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and 
in-gel activity staining of complex IV was completed using muscle homogenate4-6. The entire 
mitochondrial genome, extracted from muscle tissue, was sequenced as previously 
described7.  
 
3. Results 
Histochemical analysis of muscle tissue revealed several COX deficient fibres (Figure 2A), 
but no ragged red fibres. There was a relative reduction of complex IV activity compared 
with complex I and complexes II+III activities (Figure 2B and C). Protein levels of 
mitochondrial respiratory chain complexes and complex IV in-gel activity in muscle tissue 
was comparable with controls (Supplementary Figure 1). 
 
Sequencing of the entire mitochondrial genome revealed the novel truncating mitochondrial 
DNA (mtDNA) mutation m.6579G>A; p.Gly226X predicted to result in a premature stop 
codon in MT-CO1. The mutation was present at 70% mutant load in muscle tissue compared 
with 40% mutant load in blood, with no detectable mutant mtDNA in maternal blood (Figure 
1A). The variant is not reported in Genbank (45,494 full length and 69,730 short control 
region containing sequences3, and occurs within a residue which is highly conserved across 
different species8. Residual muscle tissue was unavailable for single fibre mtDNA 
heteroplasmy studies or measurement of the relative abundance of mtDNA encoded COX 
subunits.  
4. Discussion 
We report the novel stop codon mutation in MT-CO1 causing adult-onset Leigh syndrome. 
The diagnostic criteria for Leigh syndrome include a progressive neurological disease with 
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developmental delay, basal ganglia involvement (clinically and on imaging studies and/or 
neuropathological examination), and elevated blood or CSF lactate caused by genetically 
mediated mitochondrial dysfunction9,10. Adult-onset Leigh syndrome is a rare but well-
recognised presentation of mitochondrial disease, frequently associated with COX 
deficiency11 and typically caused by mtDNA mutations10. 
The m.6579G>A; p.Gly226X variant is highly likely to be pathogenic. A similar 
encephalomyopathic phenotype caused by a truncating MT-CO1 mutation has previously 
been described12. The m.6579G nucleotide is highly conserved and the premature stop codon 
introduced by the mutation is predicted to result in loss of more than half of the total 
polypeptide. The mutation is heteroplasmic, with higher mutant levels in muscle than blood, 
typical for pathogenic mtDNA mutations, and it segregates with disease with no mutant MT-
CO1 detectable in the unaffected mother’s blood. Histochemical and biochemical analyses of 
muscle tissue were consistent with impaired COX function. Finally, the mutation is absent 
from control samples.  
Seven, primarily de novo, truncating mutations in MT-CO1 are reported (Table 1). The 
clinical spectrum is varied and includes anaemia, myopathy, rhabdomyolysis, and central 
neurological or multisystem disease phenotypes. The patient described in this report 
presented with adult-onset Leigh syndrome. The relatively mild histochemical and 
biochemical COX deficiency detected in the patient’s skeletal muscle tissue is consistent with 
the late onset presentation and clinically undetectable muscle weakness. A low normal, rather 
than reduced, complex IV activity in the muscle tissue of patients with pathogenic MT-CO3 
mutations is reported with CNS phenotypes13, and a more severe enzymatic defect would be 
expected in brain tissue. Interestingly, the muscle heteroplasmy levels in our patient are 
similar to previously reported cases. This potentially reflects the influence nuclear genetic 
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modifiers have on the phenotypic presentation of pathogenic mtDNA mutations14. For 
instance, cybrid cells harbouring the m.7339A>G mutation in MT-CO1 still incorporate the 
truncated COX I protein into the COX sub- and holocomplex, although the presence of the 
abnormal subunit causes instability of the holoenzyme. COX subunit I interacts with several 
other factors that determine complex stability and it is proposed that the rapid clearance of 
unstable complexes by quality control pathways might explain the pathogenesis of MT-CO1 
truncation mutations rather than impaired complex assembly15. It is therefore feasible that 
inter-individual variations in these quality control processes across different tissues 
contributes towards the clinical heterogeneity of MT-CO1 truncating mutations. Furthermore, 
the relative, rather than absolute, reduction in CIV activity in muscle demonstrates the 
importance of interpreting the results of these assays in their clinical context.  
In conclusion, we report a novel stop mutation in MT-CO1 causing adult-onset Leigh 
syndrome. Inter-individual variations in the quality control pathways that regulate mutant 
protein degradation and/or mitochondrial respiratory chain complex IV stability within 
different tissues is one potential explanation for the remarkable clinical heterogeneity 
associated with MT-CO1 truncating mutations. 
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Table 1: Summary of clinicopathological, biochemical and molecular characteristics of reported MT-CO1 truncating mutations 
MT-CO1 
truncating 
mutation 
Amino 
acids 
lost (of 
513 
total) 
Age at 
sympto
m onset, 
sex 
Clinical 
phenotype 
Lactate 
Heteroplasmy (%) 
Muscle 
histolog
y 
Muscle  
CIV 
RCEA 
Function
al studies 
Inherited 
or de novo 
Refere
nce Blood Urine 
Fib
s 
Muscl
e 
5920G>A; 
p.W6X 
508 
33y, M 
(EI since 
childhoo
d) 
Rhabdomyo
lysis 
Blood 
N 
0 NA 0 
61 
 
COX -ve 
++ 
RRF 
↓ 
SF 
studies 
Absent 
from 
mother 
and 
sister’s 
blood 
16 
m.6020_60
25delCGA
GC; 
p.E40Gfs*4 
471 29y, M MND Blood ↑ NA NA NA 
47-
68.7 
 
 
COX -ve 
++ 
RRF 
↓ 
SF 
studies, 
WB of 
COX 
Absent 
from 
mother 
and 3 
17 
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subunits sibling’s 
muscle 
6579G>A; 
p.G226X 
288 17y, F 
Leigh 
syndrome 
Blood 
N, CSF 
↑ 
40 NA NA 70 COX -ve 
Relative 
reduction 
NA 
Absent 
from 
mother’s 
blood 
Current 
study 
6698delA; 
p.K265fs27
1X 
243 
 
36y, M 
MM, 
rhabdomyol
ysis 
NA NA 15 
 
NA 
 
70 COX -ve ↓ 
WB of 
COX 
subunits 
Absent 
from 
mother’s 
blood 
18 
6708G>A; 
p.G269X 
245 
28y, F 
(EI since 
childhoo
d) 
MM, 
myalgia, EI, 
rhabdomyol
ysis 
NA 0 
 
NA 
 
NA 81-89 
COX -ve 
++ 
RRF 
↓ 
SF 
studies, 
WB of 
COX 
subunits 
Absent 
from 
mother’s 
blood 
19 
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6930G>A; 
p.G343X 
171 3y, F 
Cataracts, 
optic 
atrophy, 
SNHL, 
epilepsy, 
ataxia, MM 
Blood ↑ 27 NA NA 75 
COX -ve 
++ 
 
↓ 
Confirme
d in 
cybrids 
Absent 
from 
mother, 
sister and 
4 maternal 
aunt’s 
blood 
20, 21 
7339A>G; 
p.K479X 
35 NA Anaemia NA NA NA NA NA NA NA 
Confirme
d in 
cybrids 
NA 15 
7402delC; 
p.P500Hfs*
12 
1 18y, F 
Encephalop
athy, 
NSCE, EI, 
MM, 
SNHL, 
cataracts, 
Blood 
ULN 
7 27 NA 76 
COX -ve 
++ 
RRF 
↓ 
SF 
studies, 
WB of 
COX 
subunits 
Present at 
2-5% 
using SF 
of 
mother’s 
muscle, 
22 
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cognitive 
decline 
absent 
from 
mother 
and 
sister’s 
blood and 
urine 
 
Abbreviations: CIV; complex IV, COX -ve; cytochrome c oxidase negative fibres, EI; exercise intolerance, F; female, Fibs; fibroblasts, M; male, 
MM; mitochondrial myopathy, MND; motor neuron disease, N; normal, NA; not available, NSCE; non-convulsive status epilepticus, ref; 
reference, RCEA; respiratory chain enzyme activity, RRF; ragged red fibres, SF; single fibre PCR, SNHL; sensorineural hearing loss, ULN; 
upper limit of normal, WB; western blot, Y; years, ++; severe deficiency. 
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Figure legends 
Figure 1: (A) Family pedigree. Proband is indicated by black symbol and arrow. The 
m.6579G>A heteroplasmy levels are annotated. (B) Axial T2-weighted cerebral MRI during 
the acute phase of the patient’s illness. Symmetrical hyperintensities in the basal ganglia 
illustrated by arrows. (C) Repeat cerebral MRI 10 weeks following acute phase of illness 
confirmed resolution of the original imaging changes. 
 
Figure 2: (A) Histochemical analysis of muscle tissue with cytochrome c oxidase (COX) 
stain showing COX negative and deficient fibres. (B) Mitochondrial respiratory chain 
enzyme activity measured using spectrophotometric analysis. Results expressed as ratio to 
citrate synthase (CS) activity to correct for mitochondrial enrichment of sample. 
Measurement uncertainty (%) derived from quality control data for each enzyme assayed as 
part of United Kingdom Accreditation Service (UKAS) accreditation process. COX activity 
is at the lower level of the reference range and is disproportionately reduced in comparison to 
the other mitochondrial respiratory chain enzymes. (C) Graphical representation of 
mitochondrial respiratory chain enzyme activity. Lines indicate reference ranges and black 
dots represent mitochondrial respiratory chain enzyme activity in patient. Abbreviations: CS; 
citrate synthase, I; complex I, II+III; complexes II+II, IV; complex IV. 
 
Supplementary Figure 1: (A) Coomassie blue staining showing relative abundance of 
protein complexes. Levels of complexes are comparable between patient and control. (B) 
Complex IV in-gel activity stain demonstrating normal complex IV activity in patient. 
Abbreviations: I; complex I,  II; complex II, III; complex III, IV; complex IV. 
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 The novel stop codon mutation m.6579G>A; p.Gly226X in MT-CO1 causes adult-onset 
Leigh syndrome. 
 
 MT-CO1 truncating mutations are associated with remarkable clinical heterogeneity. 
 
 The broad phenotypic spectrum potentially relates to inter-individual and tissue-specific 
variations in the quality control pathways that regulate mutant protein degradation and/or 
mitochondrial respiratory chain complex IV stability. 
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